Chronic myeloid leukaemia News and Research

RSS

Research reveals the mechanism that triggers breast cancer 'time bomb'

Scientists have discovered why breast cancer cells that have spread to the lungs may 'wake up' following years of sleep - forming incurable secondary tumors.

13 Mar 2023

World’s largest proteomics centre accelerates biomarker discoveries to improve people’s lives

Opened in 2016, Manchester’s Stoller Biomarker Discovery Centre (SBDC) is a globally renowned, multi-million-pound precision medicine research facility.

From Stoller Biomarker Discovery Centre 30 Nov 2020

Researchers apply CRISPR technology to eliminate fusion genes present in tumor cells

The CRISPR/Cas9 gene-editing tool is one of the most promising approaches to advancing treatments of genetic diseases - including cancer -, an area of research where progress is constantly being made.

9 Oct 2020

Newly developed ChiTaRS database can collect cases of druggable fusion targets

When sections from two separate genes merge due to various factors, such as translocation or splicing, the hybrid that is formed is called a gene fusion. In recent years, it has been discovered that these fusion events play a vital role in the development of cancers and other complex diseases.

20 Nov 2019

CRISPR uncovers which gene fusions are critical for growth of cancer cells

In the first large-scale analysis of cancer gene fusions, which result from the merging of two previously separate genes, researchers at the Wellcome Sanger Institute, EMBL-EBI, Open Targets, GSK and their collaborators have used CRISPR to uncover which gene fusions are critical for the growth of cancer cells.

16 May 2019

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

OGT increases NGS cancer panel content to provide more flexibility for customization

Oxford Gene Technology, The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content - now covering 120 fully optimized cancer related genes.

From Oxford Gene Technology 13 Jun 2018

Study provides new insight into development of immune cells

In contrast to what has been previously believed, development of blood stem cells to mast cells, a type of specialized immune cell, does not depend on a growth factor called stem cell factor.

10 Aug 2017

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects.

12 Jul 2017

Scientists launch new virtual platform to aid global search for treatment of leukemia

Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the world.

29 Apr 2017

Delays in availability of new treatments and incomprehensible price rises disadvantage cancer patients

Cancer patients are living longer and in many cases the disease is becoming chronic rather than acute. Access to drugs that help extend life and improve quality of life, and fair prices for those drugs are therefore essential for more and more people.

28 Jan 2017

Leukaemia patients could safely reduce side effects of drug by cutting dose in half, study shows

Patients with a chronic type of leukaemia could safely reduce the side effects of life-long treatment by cutting their dose in half, according to the results of a University of Liverpool led study presented at an international conference in America this week.

6 Dec 2016

Salvage alloSCT remains option for progressing CML patients

Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure.

15 Jun 2016

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.

15 Jun 2016

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia.

15 Jun 2016

$Allogeneic HSCT offers good survival for select TKI-refractory CML patients$

Chronic myeloid leukaemia News and Research

Research reveals the mechanism that triggers breast cancer 'time bomb'

World’s largest proteomics centre accelerates biomarker discoveries to improve people’s lives

Researchers apply CRISPR technology to eliminate fusion genes present in tumor cells

Newly developed ChiTaRS database can collect cases of druggable fusion targets

CRISPR uncovers which gene fusions are critical for growth of cancer cells

Potential combination therapy against rare disease of the bone marrow could improve treatment

OGT increases NGS cancer panel content to provide more flexibility for customization

Study provides new insight into development of immune cells

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Scientists launch new virtual platform to aid global search for treatment of leukemia

Delays in availability of new treatments and incomprehensible price rises disadvantage cancer patients

Leukaemia patients could safely reduce side effects of drug by cutting dose in half, study shows

Salvage alloSCT remains option for progressing CML patients

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Long-term dasatinib findings support first-line use in CML

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Real-world CML management in line with ELN guidelines

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

CML treatment-free remission criteria outlined

BCR-ABL halving time indicates CML prognosis during front-line TKI

Michael Stryker

The past, present and future of automation and digitalization in the life sciences laboratory

Arxspan BioDrive: A Versatile Solution for Molecular Biology

Latest News